Association between fat-free mass loss, changes in appetite, and weight regain in individuals with obesity
TFL coverage of GLP-1 drugs that are approved by the Food and Drug Administration (FDA) to treat weight loss (Wegovy, Zepbound, Saxenda, Qsymia, Phentermine, or Contrave) is slated to end Aug
The anticipated price reductions from Medicare negotiations may influence employer-sponsored health plans to adjust their coverage policies for GLP-1s
No prospective studies have been conducted in humans in controlled circumstances to demonstrate whether CYP450 polymorphisms lead to an increase or a decrease in paracetamol oxidation nor have there been studies demonstrating that CYP450 polymorphisms in humans increase or decrease the risk of paracetamol toxicity before or after an overdose
Whether you're dealing with fatigue, recovering from illness, or looking to optimize your health, understanding how IV nutrient therapy works can help you make an informed decision
were supported by National Science Foundation Graduate Research Fellowships